XML 41 R9.htm IDEA: XBRL DOCUMENT

Other Income	3 Months Ended
Dec. 31, 2019
Component of Operating Income [Abstract]
Other Income	Note 3 Other Income Grant Income During the year ended September 30, 2017, the Company was awarded grant funding in the amount of $597,886. The grant is being received in equal quarterly installments over a period of two years beginning during the year ended September 30, 2018 in exchange for a commitment to complete clinical testing for a therapeutic drug candidate for the treatment of Rett syndrome. The grant income is deferred when received and amortized to other income as the related research and development expenditures are incurred. During the three months ended December 31, 2019, the Company recognized $74,944 (2018: $74,528) of this grant on its statement of operations within grant income. Research and development incentive income Research and development incentive income represents the receipt by the Company’s Australian subsidiary, of the Australian research and development incentive credit, (the “ATO R&D Credit”). During the three months ended December 31, 2019, the Company recorded research and development incentive income of $943,215 (AUD 1,345,000) (2018: $413,682 (AUD 587,000)) in respect of the ATO R&D Credit for eligible research and development expenses incurred during the period.

Other Income

3 Months Ended

Dec. 31, 2019

Component of Operating Income [Abstract]

Note 3 Other Income

Grant Income

During the year ended September 30, 2017, the Company was awarded grant funding in the amount of $597,886. The grant is being received in equal quarterly installments over a period of two years beginning during the year ended September 30, 2018 in exchange for a commitment to complete clinical testing for a therapeutic drug candidate for the treatment of Rett syndrome.

The grant income is deferred when received and amortized to other income as the related research and development expenditures are incurred. During the three months ended December 31, 2019, the Company recognized $74,944 (2018: $74,528) of this grant on its statement of operations within grant income.

Research and development incentive income

Research and development incentive income represents the receipt by the Company’s Australian subsidiary, of the Australian research and development incentive credit, (the “ATO R&D Credit”).

During the three months ended December 31, 2019, the Company recorded research and development incentive income of $943,215 (AUD 1,345,000) (2018: $413,682 (AUD 587,000)) in respect of the ATO R&D Credit for eligible research and development expenses incurred during the period.